News Center

Home page

Peak Report

News reports

Announcement on the 2020 profit distribution plan.

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2021-007

Zhejiang Jianfeng Group Co., Ltd.

Announcement on 2020 Profit Distribution Plan

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Important Content Note:

Distribution Ratio per Share: Cash Dividend 4.0 Yuan (Including Tax) for Every 10 Shares. No bonus shares will be distributed in 2020, and no CPF capitalization will be carried out.
This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2021, the company will continue to promote the peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparations project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor new drugs DPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support.

Content of 1. Profit Distribution Plan

Audited by Tianjian Certified Public Accountants (Special General Partnership), the net profit attributable to shareholders of the parent company in the consolidated statement of the company in 2020 was ,584,420, 195.33 yuan; The net profit of the parent company's accounting statement 421,557,349.00 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 42,155,734.90 yuan, plus undistributed profit 1,152,229,187.97 yuan at the beginning of the year, minus 2019 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,428,405,653.67 yuan.

Company plans to make cash distribution in 2020 . Based on 2020 year-end share capital 344,083,828 shares, cash dividend 4.0 yuan (tax included) will be distributed for every 10 shares, and the total cash dividend will be distributed to all shareholders registered on the equity registration date is 137,633,531.20 yuan (tax included).

2020 No provident fund conversion to share capital.

If the total share capital of the company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the company plans to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.

This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. In order to take into account the short-term income of shareholders and the long-term development of the company and maintain the continuity and relative stability of dividends, the board of directors put forward the above-mentioned profit distribution plan for 2020

. During the reporting period, the net profit attributable to shareholders of the listed company in the consolidated statement of the company was

584,420,195.33

yuan, and the total cash dividend to be distributed was

137,633,531.20 yuan (including tax), accounting for 23.55% of the net profit attributable to shareholders of listed companies this year, lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development. In 2021 , the company will continue to promote the annual output of 20

.2 billion solid preparation project in Jinxi production base of peak pharmaceutical industry. New Peak North Carolina (formerly Anhui Zhongwang) Phase II Technological Transformation Project; The construction and transformation of projects under construction such as the New North Card Chemical Technology Transformation Project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor drugs

DPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company (I) the convening, deliberation and voting of the board meeting

2021

# April

, the company held the 108 meeting of the 11th board of directors

#. the company currently has nine directors, all of whom attended the meeting, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2020 was deliberated and approved by 110 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2020 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting. (II) Opinions of Independent Directors

Independent Directors of the Company express the following opinions on the profit distribution plan of the Company

2020 :

. We agree that the Company will distribute cash dividends

4.0 yuan (including tax) for every 10 shares of the Company

2020

year-end share capital ,344,083, 828 shares as the base, the total amount of cash dividends distributed to all shareholders registered on the date of record is ,633,531.20 yuan (including tax). 2020 year will not carry out provident fund to increase the share capital. 2 , the profit distribution plan is based on the actual operating results and financial situation of the company 2020 , combined with the actual needs of the company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3

, the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, holding and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's

2020 Annual General Meeting for consideration. (III) the opinions of the board of supervisors

2021 July

, the company held the 161 meeting of the 10th board of supervisors

2#. the company currently has five supervisors, all of whom attended the meeting in person, in line with the relevant provisions of the company law and the articles of association of the company, and the resolution made is legal and valid. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year

2020 was deliberated and approved by 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2020 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; The company's profit distribution and cash dividend decisions were not found to damage the legitimate rights and interests of shareholders. 4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2020

annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Dong

Affairs

Meeting

April

27, 2001

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页